NCT04335721View on ClinicalTrials.gov

A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

October 7, 2024

Study Completion Date

October 7, 2024

Conditions
Sickle Cell DiseaseSickle Cell Nephropathy
Interventions
DRUG

Voxelotor

Voxelotor 1500mg once a day

Trial Locations (1)

60612

University of Illinois, Chicago

Sponsors

Collaborators (1)

Global Blood Therapeutics
All Listed Sponsors
collaborator

Global Blood Therapeutics

INDUSTRY

lead

University of Illinois at Chicago

OTHER

NCT04335721 - A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease | Biotech Hunter | Biotech Hunter